Physician profile
Amanda C Peltier
NPI 1093802126
$234,505.24
in general payments reported to CMS, 2019-2025
16 companies · $18K in 2025
The $18K reported for 2025 was more than what 83% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $18K · 2021: $25K · 2022: $29K · 2023: $19K · 2024: $40K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $9,996 · Food and Beverage: $3,859 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,809.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,470.77 |
| Travel and Lodging | $9,996.21 |
| Food and Beverage | $3,858.65 |
| Education | $147.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $60,308.13 | 2019-2025 | Amvuttra, Onpattro |
| Akcea Therapeutics, INC. | $55,952.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $53,684.73 | 2022-2025 | Wainua, Onglyza, Lokelma |
| Catalyst Pharmaceuticals, INC. | $33,210.88 | 2019-2024 | |
| Csl Behring | $20,803.35 | 2019-2025 | Hizentra, Privigen |
| Astrazeneca Uk Limited | $6,444.00 | 2025 | Wainua |
| Argenx US, INC. | $3,019.90 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $824.91 | 2019-2024 | Ultomiris |
| Janssen Biotech, INC. | $130.22 | 2025 | |
| Pfizer INC. | $73.01 | 2022 | |
| Amgen INC. | $21.33 | 2025 | Uplizna |
| Tanabe Pharma America, INC. | $16.50 | 2019 | |
| Philips North America LLC | $16.22 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Peltier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.